📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
OneSource Pharma Gets NSE/BSE No-Objection for Merger with Steriscience and Strides Entities
OneSource Specialty Pharma has cleared a major regulatory hurdle by receiving 'No-Objection' letters from NSE and BSE for its proposed multi-entity merger. The scheme involves the absorption of Steriscience Specialties, Brooks Steriscience, Steriscience Pte. (Singapore), and Strides Pharma Services into OneSource. This consolidation is aimed at creating a larger specialty pharma platform, though it remains subject to NCLT and shareholder approvals. Investors should carefully review the mandated disclosures regarding the impact on public shareholding and the integration of accumulated losses from the merging entities.
Key Highlights
NSE and BSE issued 'No-Objection' letters on February 25, 2026, valid for a period of six months.
The merger includes four transferor companies, including an international entity based in Singapore (Steriscience Pte. Limited).
SEBI requires prominent disclosure of the pre and post-scheme shareholding patterns for promoters and public shareholders in the upcoming notice.
The company must provide a detailed rationale for merging entities with accumulated losses and the resulting impact on OneSource's reserves.
Final implementation remains subject to approvals from the NCLT Mumbai, Singapore Courts, and respective creditors.
💼 Action for Investors
Investors should wait for the detailed explanatory statement to assess the share-swap ratio and the financial health of the entities being absorbed. This merger is a significant step for the company's growth but requires final NCLT clearance.
OneSource Secures SFDA Approval for Generic Ozempic in Saudi Arabia via Hikma Partnership
OneSource Specialty Pharma has received approval from the Saudi Food and Drug Authority (SFDA) to commercialize a generic version of Ozempic (semaglutide) in Saudi Arabia. The company has entered into an exclusive partnership with Hikma Pharmaceuticals, the largest pharma company in the MENA region, to handle commercialization and distribution. OneSource will manufacture the product at its integrated Biologics facility in Bengaluru, India. This approval marks a significant entry into one of the world's largest markets for GLP-1 therapies, positioning the company for high-growth revenue in the metabolic health segment.
Key Highlights
Received SFDA approval for generic semaglutide (Ozempic®) in Saudi Arabia.
Exclusive commercialization partnership with Hikma Pharmaceuticals for the MENA region.
Manufacturing to be conducted at the company's state-of-the-art Bengaluru facility.
Targeting Saudi Arabia, identified as one of the largest global markets for GLP-1 therapies.
OneSource operates 5 global manufacturing facilities with a team of over 1,600 professionals.
💼 Action for Investors
Investors should monitor the commercial rollout and subsequent revenue contribution from the MENA region, as this establishes OneSource as a key player in the high-value GLP-1 generic market. The stock may see positive momentum given the scale of the partnership with Hikma.
Promoter Group Acquires 4.43 Lakh Shares (0.39% Stake) of OneSource Specialty Pharma
Promoter group entities, Tenshi Pharmaceuticals Private Limited and Pronomz Ventures LLP, have increased their stake in OneSource Specialty Pharma by purchasing 443,906 shares from the open market. This acquisition represents approximately 0.39% of the company's total paid-up equity capital. The transactions were carried out between January 30, 2026, and February 04, 2026. Such insider buying is generally viewed as a sign of promoter confidence in the company's valuation and future growth prospects.
Key Highlights
Promoter group acquired a total of 443,906 equity shares representing 0.39% of the company.
Tenshi Pharmaceuticals Private Limited purchased 365,000 shares across three transactions.
Pronomz Ventures LLP acquired 78,906 shares in two separate market transactions.
The acquisition was conducted through the stock market between January 30 and February 04, 2026.
Disclosures were made under SEBI Substantial Acquisition of Shares & Takeovers and Prohibition of Insider Trading regulations.
💼 Action for Investors
Investors should take this as a positive signal of promoter commitment and confidence in the business. It may be worth monitoring the stock for further consolidation or accumulation by insiders at current levels.
OneSource Q3 FY26 Revenue Drops $10M on Regulatory Delays; Reaffirms $400M FY28 Target
OneSource Specialty Pharma reported a $10 million sequential revenue decline in Q3 FY26, primarily driven by deferred semaglutide approvals in the Canadian market and a strategic shift from MSAs to commercial supplies. Despite these near-term headwinds, management reiterated its FY28 guidance of $400 million in revenue and $160 million in EBITDA, excluding inorganic growth. The company is aggressively investing over INR 700 crores in capacity expansion and has doubled its flagship site workforce to prepare for a significant ramp-up expected in H2 FY27.
Key Highlights
Q3 FY26 revenue and EBITDA declined by approximately $10 million sequentially due to deferred commercial launches.
Reiterated long-term FY28 guidance of $400 million revenue and $160 million EBITDA.
Aggressive capex of over INR 700 crores (~$100 million) is underway, with 75% of flagship site investment already committed.
Currently holding INR 250 crores in customer advances for pre-booked manufacturing capacities.
Flagship site workforce doubled year-to-date with the addition of 300 new full-time employees.
💼 Action for Investors
Investors should focus on the H2 FY27 recovery timeline and regulatory approval milestones for semaglutide in Canada and emerging markets. While the next two quarters may remain soft, the reiterated FY28 guidance suggests significant long-term upside if execution remains on track.
Promoter Tenshi Pharmaceuticals Acquires 200,000 Shares (0.17% Stake) in OneSource Specialty
Tenshi Pharmaceuticals Private Limited, a promoter entity of OneSource Specialty Pharma Limited, has acquired 200,000 equity shares from the open market. This transaction, completed on January 28, 2026, represents a 0.17% stake in the company's total equity capital. The acquisition was disclosed in compliance with SEBI's Substantial Acquisition of Shares and Insider Trading regulations. Promoter buying from the open market typically signals internal confidence in the company's long-term value and operational trajectory.
Key Highlights
Tenshi Pharmaceuticals purchased 200,000 equity shares on January 28, 2026.
The acquisition accounts for 0.17% of the company's total equity share capital.
The transaction was executed via an open market purchase.
The disclosure follows SEBI (SAST) and SEBI (PIT) regulatory requirements.
💼 Action for Investors
This insider buying is a positive indicator of promoter conviction; investors may consider this a supportive factor for the stock price. Monitor for further accumulation by promoters as a sign of sustained confidence.
OneSource Corrects FY28 Revenue Guidance to $500M; Reports Weak Q3FY26 Results
OneSource Specialty Pharma reported a weak Q3FY26 with revenues declining 26% YoY to ₹2,903 million and EBITDA falling 88% to ₹173 million due to delayed semaglutide approvals in Canada. The company issued a critical correction to its FY28 guidance, clarifying that revenue targets are $400-$500 million, not ₹400-₹500 million as previously stated. Despite a quarterly adjusted PAT loss of ₹472 million, management reaffirmed long-term targets of ~40% EBITDA margins and ROCE above 50%. The company noted that the order book remains strong and the biologics segment is seeing historic high interest.
Key Highlights
Corrected FY28 revenue guidance to $400 million organic and $500 million total, a massive upward correction from the typo of ₹500 million.
Q3FY26 revenue dropped 26% YoY to ₹2,903 million, impacted by transition delays from MSA to CSA phases in Canada.
EBITDA margins collapsed to 6% from 36% YoY, leading to an adjusted PAT loss of ₹472 million.
Effective interest rate (EIR) improved by 200bps YoY to below 9%, showing better debt management.
Reaffirmed FY28 outlook of ~40% EBITDA margin and Net-to-EBITDA ratio below 1.5x.
💼 Action for Investors
Investors should focus on the timeline for Canadian regulatory approvals for semaglutide, which is the primary bottleneck for current revenue. While the corrected USD-denominated FY28 guidance is highly positive, the current operational volatility suggests waiting for a recovery in EBITDA margins before increasing exposure.
OneSource Q3FY26 Revenue Drops 26% to ₹2,903M; EBITDA Margin Shrinks to 6%
OneSource Specialty Pharma reported a weak Q3FY26 with revenue declining 26% YoY to ₹2,903 million, primarily due to delayed customer approvals for semaglutide in Canada. EBITDA crashed 88% YoY to ₹173 million as margins compressed significantly from 36% to 6% due to a fixed cost base and lower operating leverage. Despite the quarterly setback, the company reaffirmed its ambitious FY28 guidance of $400-$500 million in revenue with ~40% EBITDA margins. The biologics segment remains a bright spot with a 4x growth in the project funnel and the onboarding of a major US biosimilar player.
Key Highlights
Revenue declined 26% YoY to ₹2,903 million due to transitional delays in the Canadian market for semaglutide.
EBITDA plummeted 88% YoY to ₹173 million, with margins shrinking by 3,018 bps to 6%.
Reported an Adjusted PAT loss of ₹472 million compared to a profit of ₹672 million in Q3FY25.
Reaffirmed FY28 organic revenue guidance of $400 million and steady-state EBITDA margin outlook of ~40%.
Biologics funnel grew 4x compared to FY25, with 20 new MSAs and licensing deals signed during the year.
💼 Action for Investors
Investors should treat this as a transitional quarter and closely monitor the timeline for Canadian regulatory approvals for semaglutide. While current earnings are weak, the long-term investment thesis depends on the company's ability to execute its high-margin FY28 guidance and scale its biologics CDMO business.
OneSource Specialty Pharma Q3 Revenue Drops 22% QoQ; Reports ₹621.8 Million Net Loss
OneSource Specialty Pharma (formerly Stelis Biopharma) reported a weak Q3 FY26 with standalone revenue falling 22.6% sequentially to ₹2,902.2 million. The company posted a net loss of ₹621.8 million, a sharp reversal from the ₹371 million profit in Q2 FY26, driven by increased 'other expenses' and exceptional costs. Exceptional items totaling ₹70.9 million were linked to merger integration and employee settlements. While 9M FY26 performance shows revenue growth of 20% YoY, the quarterly volatility remains a concern for short-term performance.
Key Highlights
Standalone Revenue from operations declined to ₹2,902.2 million in Q3 FY26 from ₹3,751.9 million in Q2 FY26.
Reported a Net Loss of ₹621.85 million for the quarter, compared to a profit of ₹371.01 million in the preceding quarter.
Exceptional items of ₹70.9 million included ₹41.47 million for one-time employee settlements and merger-related expenses.
9M FY26 revenue improved to ₹9,864.2 million from ₹8,221.8 million in the corresponding period last year.
Ongoing Composite Scheme of Arrangement involves amalgamation with multiple entities including Brooks Steriscience and Steriscience Pte.
💼 Action for Investors
Investors should monitor the progress of the Composite Scheme of Arrangement and the company's ability to stabilize margins post-merger. The current operational loss and revenue contraction suggest a cautious approach is warranted until post-merger synergies are realized.
OneSource Specialty Pharma Reports Q3 FY26 Net Loss of ₹621.85 Million; Revenue Down 22.6% QoQ
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) reported a standalone net loss of ₹621.85 million for the quarter ended December 31, 2025, a sharp reversal from the ₹371.01 million profit in the previous quarter. Revenue from operations declined 22.6% sequentially to ₹2,902.20 million. The bottom line was further impacted by ₹70.90 million in exceptional costs related to employee settlements and labor code adjustments. The company is currently in the process of a major corporate restructuring through a composite scheme of arrangement to merge multiple entities.
Key Highlights
Revenue from operations decreased to ₹2,902.20 million from ₹3,751.87 million in the previous quarter.
Swung to a net loss of ₹621.85 million in Q3 FY26 from a profit of ₹371.01 million in Q2 FY26.
Exceptional items of ₹70.90 million recorded for employee separation settlements and new labor code impacts.
Finance costs remained significant at ₹379.85 million for the quarter.
Ongoing 'Composite Scheme of Arrangement' aims to merge Steriscience and Brooks Steriscience with the company.
💼 Action for Investors
The company is in a volatile transition phase due to declining quarterly revenues and an ongoing massive merger. Investors should remain cautious and monitor the regulatory approvals for the amalgamation scheme which will redefine the company's capital structure.
OneSource Specialty Pharma Merges Singapore Subsidiaries with $41.95M Combined Turnover
OneSource Specialty Pharma has completed the amalgamation of its two Singapore-based wholly owned subsidiaries, Stelis Pte. Limited and OneSource Specialty Pte. Limited, effective January 1, 2026. Stelis reported a turnover of USD 7.86 million for FY25, while OneSource Specialty Pte. recorded USD 34.09 million. The merger is designed to simplify the corporate hierarchy and reduce redundant administrative, legal, and compliance costs. Since both are 100% owned subsidiaries, the transaction has no impact on the consolidated financial position or the shareholding pattern of the parent company.
Key Highlights
Amalgamation of Stelis Pte. Limited into OneSource Specialty Pte. Limited effective January 1, 2026.
Stelis Pte. Limited reported a turnover of USD 7.86 million for the financial year ended March 31, 2025.
OneSource Specialty Pte. Limited reported a turnover of USD 34.09 million for the financial year ended March 31, 2025.
Restructuring aims to enhance operational efficiency and eliminate redundant administrative and compliance costs.
The transaction is between wholly owned subsidiaries and does not affect the consolidated financials or shareholding pattern.
💼 Action for Investors
This is a routine internal restructuring aimed at cost optimization and operational efficiency. Investors need not take any immediate action as the consolidated fundamentals of the company remain unchanged.
OneSource Specialty Pharma Receives [IND A-/Positive] Credit Rating Affirmation from Ind-Ra
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) has announced that India Ratings & Research (Ind-Ra) has affirmed its credit rating for additional bank loan facilities. The rating is maintained at [IND A-/Positive], which is consistent with the previous rating issued on June 03, 2025. This affirmation reflects the agency's view on the company's creditworthiness and financial stability. The 'Positive' outlook indicates potential for a future rating upgrade based on sustained operational performance.
Key Highlights
India Ratings & Research (Ind-Ra) affirmed the credit rating at [IND A-/Positive].
The rating applies to the company's additional bank loan facilities.
The current rating remains consistent with the previous assessment from June 03, 2025.
The 'Positive' outlook suggests a favorable credit trajectory for the specialty pharma firm.
💼 Action for Investors
Investors should take confidence in the 'Positive' outlook, which suggests the company is maintaining its financial health. Monitor the company's ability to convert this outlook into a formal rating upgrade through improved cash flows and debt management.